ArticlePloS one2013
Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 114 citations in OpenAlex.
- Curcumin Nanoemulsion: Characterization and Effect on Cataracts in an In Vivo Animal Model and Ex Vivo Human Model.Biomolecules · 2026Article
- Sex-specific efficacy of curcumin-loaded nanoparticles and insulin for ocular-cardiac complications in type 2 diabetes mice.iScience · 2026Article
- Comprehensive Modalities for Cataract Management: Preventive, Surgical, and Non-Surgical Approaches Using Conventional and Nanotechnology-Based Therapies.AAPS PharmSciTech · 2026Review
- Nanotechnology-Based Treatment for Ophthalmic Diseases.International journal of nanomedicine · 2026Review
- Advances in the management of ocular anterior segment diseases using biomaterials-based drug delivery systems.Journal of biomaterials applications · 2026Review
- Cataract Management in the Modern Era: Therapeutic Advances and Unmet Needs.Current pharmaceutical design · 2026Review
- Amelioration of cisplatin-induced myocardial injury by nanocurcumin through antioxidant, anti-inflammatory, and calcium regulatory mechanisms.Journal of molecular histology · 2025Article
- Pharmacological Strategies for Cataract Management: From Molecular Targets to Clinical Translation.International journal of molecular sciences · 2025Review
- Prospects for the convergence of polyphenols with pharmaceutical drugs in type 2 diabetes: Challenges, risks, and strategies.Pharmacological reviews · 2025Review
- Current State of Scientific Knowledge on Curcumin Encapsulation and Applications.Recent advances in food, nutrition & agriculture · 2025Review
- Evaluation of the anti-diabetic and anti-inflammatory potentials of curcumin nanoparticle in diabetic rat induced by streptozotocin.Open veterinary journal · 2024Article
- Unlocking the potential of flavonoid-infused drug delivery systems for diabetic wound healing with a mechanistic exploration.Inflammopharmacology · 2024Review
- Article
- Glucose-Responsive Microgel Comprising Conventional Insulin and Curcumin-Laden Nanoparticles: a Potential Combination for Diabetes Management.The AAPS journal · 2023Article
- Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Oral Nanocurcumin Alone or in Combination with Insulin Alleviates STZ-Induced Diabetic Neuropathy in Rats.Molecular pharmaceutics · 2022Article
- Antibacterial Potential ofMolecules (Basel, Switzerland) · 2022Article
- Oral Nano-Curcumin in a Model of Chronic Gulf War Illness Alleviates Brain Dysfunction with Modulation of Oxidative Stress, Mitochondrial Function, Neuroinflammation, Neurogenesis, and Gene Expression.Aging and disease · 2022Article
- Therapeutic Applications of Curcumin in Diabetes: A Review and Perspective.BioMed research international · 2022Review
- Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcumin, the active principle present in the yellow spice turmeric, has been shown to exhibit various pharmacological actions such as antioxidant, anti-inflammatory, antimicrobial, and anti-carcinogenic activities. Previously we have reported that dietary curcumin delays diabetes-induced cataract in rats. However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin. In this study, we have administered curcumin encapsulated nanoparticles in streptozotocin (STZ) induced diabetic cataract model. Oral administration of 2 mg/day nanocurcumin was significantly more effective than curcumin in delaying diabetic cataracts in rats. The significant delay in progression of diabetic cataract by nanocurcumin is attributed to its ability to intervene the biochemical pathways of disease progression such as protein insolubilization, polyol pathway, protein glycation, crystallin distribution and oxidative stress. The enhanced performance of nanocurcumin can be attributed probably to its improved oral bioavailability. Together, the results of the present study demonstrate the potential of nanocurcumin in managing diabetic cataract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.